Betalin Therapeutics Ltd.
Betalin Therapeutics licensed the novel Engineered Micro Pancreas (EMP) technology developed at The Hebrew University of Jerusalem, Israel, in an exclusive worldwide agreement in 2015. The Hebrew University continues to partner with Betalin Therapeutics to support the research and development. The EMP aims to restore normal blood glucose levels by mimicking the function of the pancreas using islet cells encapsulated within a micro-organ matrix scaffold. Betalin has produced some promising results and we hope to submit a package soon to the HTA to begin our first in-man studies. which aims to introduce new technologies in the field of cell and gene therapies, and to increase patient access to advanced therapy medicinal products (ATMPs).
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
About us
In August of 2020, Betalin Therapeutics opened a subsidiary, BetalinUK, in Leeds, United Kingdom. This new adventure brings an exciting opportunity to work with key clinicians and scientists to help us accelerate into our first-in-man studies
BetalinUK is a member of the Northern Alliance Advance Therapies Treatment Centre (NA-ATTC, compromising of Edinburgh, Glasgow, Leeds and Newcastle) which aims to introduce new technologies in the field of cell and gene therapies, and to increase patient access to advanced therapy medicinal products (ATMPs) on a national level
BetalinUK works closely with both Newcastle University and the Univeristy of Leeds. We will be looking to expand our teams with exceptional scientists, more information about current vacancies will be announced soon.